To achieve this objective, we initiated our investigation by examining the association between CCL19 expression levels and the overall survival (OS) (Supplementary Figure 1) and progression-free survival (PFS) (Supplementary Figure 2) among patients diagnosed with distinct cancer types. Here, CCL19 is linked to cancer.